Background: The Intersection of Diabetes and Mental Health
The comorbidity between type 2 diabetes and mental health disorders represents one of the most pressing challenges in modern medicine. Epidemiological data consistently demonstrate that individuals with diabetes face a substantially elevated risk of developing depression, anxiety, and even suicide. This bidirectional relationship creates a complex therapeutic landscape where managing blood glucose must be balanced against mental health stability.
GLP-1 receptor agonists have emerged as cornerstone medications for both diabetes and obesity management. However, the psychiatric effects of these agents have remained controversial, with limited and sometimes contradictory evidence regarding their impact on mood, anxiety, and self-harm behaviors. The question of whether GLP-1 receptor agonists alleviate or potentially exacerbate mental illness has significant implications for clinical decision-making in this vulnerable population.
